Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.
about
Possible risk factors for increased suicide following bariatric surgery.Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulationsTrends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substratesVitamin, mineral, and drug absorption following bariatric surgeryThe effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors.Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin.Treatment of lipid disorders in obesity.Pharmacokinetic effects of bariatric surgery.Impact of obesity on drug metabolism and elimination in adults and children.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.The effects of gastric bypass surgery on drug absorption and pharmacokinetics.The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs.Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes.Review article: The nutritional and pharmacological consequences of obesity surgery.A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels.Psychopharmacology and Bariatric Surgery.Comparison of Warfarin Dosages and International Normalized Ratios Before and After Roux-en-Y Gastric Bypass Surgery.Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations.RYGB and Drug Disposition: How to Do Better? Analysis of Pharmacokinetic Studies and Recommendations for Clinical Practice.Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study.Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch.Clinicians' prescribing practices for bariatric surgery patients: is there an issue?Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.Lithium toxicity after Roux-en-Y bariatric surgery.Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution
P2860
Q35215011-13AC5832-6699-4C43-99C4-B31CB4B045CCQ36243622-C48F3063-6B95-456D-BBF8-07B005E746D7Q36390234-BA65EF69-D95E-4CAF-885B-0DC23CA068ABQ36418440-4076B958-BD95-4C12-86FF-2E355F3778A9Q36608087-F5E4177A-FC04-43A9-80C9-F290049F87FEQ36642008-7C8BFA5E-B50A-4B59-B974-C11ACEE36CC4Q36865856-6DDE61E1-92BB-42CA-A2EA-64F9D165AB65Q37923978-0F8C865B-774D-47C5-B474-206CAAE8CB48Q37970648-F7988657-7AF2-4393-AFB2-F081C4592EAEQ37997025-21B6DFAF-A408-4887-8D6B-C44680F2A7DBQ38014312-693DF4C8-A1D1-457D-8E5A-7E391A9F14A4Q38045375-26207ADC-E525-43F6-8AE2-6121B37A8B19Q38079182-6D581471-E945-4EE2-90A2-4694CA3E3CA6Q38083603-6C2649F9-EC6C-421A-80DD-E7446BB491CEQ38235543-EC5BB655-A5CB-4298-9247-9D574A8422A1Q38554099-A25B56D0-BA99-4C76-8665-21DFFE83A820Q38580433-F8341930-CED8-42E3-9261-E993D1FD6C9EQ38592806-A60B5803-9CDA-476F-ADAE-EF2012135620Q38874008-7A3D33C9-AC9A-44E2-BFC2-665059310826Q39104101-9EDA87B0-BEC6-4904-B75F-520F421DD11FQ39721147-657B76F7-09D5-4C30-AB85-E89FA5E7AB96Q40075610-9153238B-2CFA-4DA7-A284-A0616A2533C0Q41454726-ED7AAA0F-2079-436E-8012-A675827F2984Q43072825-59A50563-4C2C-4F44-B0CB-3E647ADCC4B9Q45343457-0C6D3A63-7B8F-449A-A694-7BFA148CE361Q48035659-3D41DA95-AAB2-475A-90D0-E97AB0AFA7F5Q53144975-9B54CCF6-AE75-4DD6-9623-5683A406FDCEQ55330048-2BF4A845-F59C-4EFF-8376-4353122C6A29Q57719724-FF022C0B-91FC-45E3-80B7-D30762E5F8BA
P2860
Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Significantly altered systemic ...... ry in morbidly obese patients.
@en
Significantly altered systemic ...... ry in morbidly obese patients.
@nl
type
label
Significantly altered systemic ...... ry in morbidly obese patients.
@en
Significantly altered systemic ...... ry in morbidly obese patients.
@nl
prefLabel
Significantly altered systemic ...... ry in morbidly obese patients.
@en
Significantly altered systemic ...... ry in morbidly obese patients.
@nl
P2093
P2860
P356
P1476
Significantly altered systemic ...... ry in morbidly obese patients.
@en
P2093
G S Jakobsen
H Christensen
I B Skottheim
J Hjelmesaeth
K Stormark
P2860
P304
P356
10.1038/CLPT.2009.82
P407
P577
2009-06-03T00:00:00Z